...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncogene >Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
【24h】

Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies

机译：epratuzumab（抗CD22 IgG）在B细胞恶性肿瘤中的临床前和临床评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The vast majority of non-Hodgkin's lymphomas are of B-cell phenotype. Development of unlabeled or radiolabeled therapeutic monoclonal antibodies against the cell surface antigen, CD20, has revolutionized the treatment of these malignancies. It is clear that antibodies targeting other B-cell-specific molecules, such as CD22, also offer potential therapeutic benefit. Epratuzumab is a humanized anti-CD22 monoclonal, which has undergone preclinical and phase I/II clinical evaluation in patients with indolent or aggressive lymphoma. Data suggest that this agent is well tolerated, and can induce tumor regressions. Trials are currently evaluating its safety and activity in combination with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing. Initial results suggest that these regimens have acceptable toxicity, and that epratuzumab warrants further evaluation as an adjunct to standard lymphoma treatment regimens.
机译：绝大多数非霍奇金淋巴瘤是B细胞表型。针对细胞表面抗原CD20的未标记或放射性标记的治疗性单克隆抗体的开发彻底改变了这些恶性肿瘤的治疗方法。显然，靶向其他B细胞特异性分子（例如CD22）的抗体也可提供潜在的治疗益处。依帕妥珠单抗是一种人源化的抗CD22单克隆抗体，已针对惰性或侵袭性淋巴瘤患者进行了临床前和I / II期临床评估。数据表明，这种药物耐受性良好，并且可以导致肿瘤消退。目前正在与利妥昔单抗（嵌合抗CD20）联合评估其安全性和活性，目前正在进行标准化疗。初步结果表明这些方案具有可接受的毒性，并且依普妥珠单抗值得作为标准淋巴瘤治疗方案的辅助评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号